Document:

Exhibit 4.2

 

 

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF
ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND
STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

	No. [__]	[DATE]

 

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

 

CAPITAL STOCK PURCHASE WARRANT

 

_________________

 

This
Certified That, for value received, [_______________] (the “Holder”) is entitled to subscribe
for and purchase from NeuroOne Medical Technologies Corporation, a Delaware
corporation (the “Company”), at any time commencing on [DATE] and expiring on the five year anniversary
(the “Warrant Exercise Term”), the Shares at the Exercise Price (each as defined in Section 1
below).

 

This Warrant is issued
pursuant to that certain promissory note issued to the Holder on [_______________] (the “Note”) in connection
with the Company’s private placement solely to accredited investors of up to $300,000 (or such higher amount as the Company’s
Board of Directors shall determine) aggregate principal amount of Notes. Capitalized terms used herein and not otherwise defined
shall have the meanings ascribed to those terms in the Notes.

 

This Warrant is subject
to the following terms and conditions:

 

1.             Shares.
The Holder has, subject to the terms set forth herein, the right to purchase, at any time during the Warrant Exercise Term, [____]
shares of Common Stock (the “Shares”) at an exercise price of $1.80 per share (the “Exercise
Price”).

  

2.             Exercise
of Warrant. 

 

(a)          Exercise.
This Warrant may be exercised by the Holder at any time during the Warrant Exercise Term, in whole or in part, by delivering the
notice of exercise attached as Exhibit A hereto (the “Notice of
Exercise”), duly executed by the Holder to the Company at its principal office, or at such other office as the Company
may designate, accompanied by payment, in cash or by wire transfer of immediately available funds or by check payable to the order
of the Company (the “Purchase Price”). For purposes hereof, “Exercise Date”
shall mean the date on which all deliveries required to be made to the Company upon exercise of this Warrant pursuant to this Section
2(a) shall have been made.

 

(b)          Issuance
of Certificates. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section
2(a) hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Holder (i) a certificate
or certificates for the number of validly issued, fully paid and non-assessable Shares to which the Holder shall be entitled upon
such exercise and, if applicable, (ii) a new warrant of like tenor to purchase all of the Shares that may be purchased pursuant
to the portion, if any, of this Warrant not exercised by the Holder. The Holder shall for all purposes hereof be deemed to have
become the Holder of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance
with Section 2(a) hereof were delivered and made, respectively, irrespective of the date of delivery of such certificate
or certificates, except that if the date of such delivery, notice and payment is a date when the stock transfer books of the Company
are closed, such person shall be deemed to have become the holder of record of such Shares at the close of business on the next
succeeding date on which the stock transfer books are open. Warrant Shares purchased hereunder shall be transmitted by the transfer
agent to the Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company through its Deposit
or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either
(A) there is an effective registration statement permitting the issuance of the Shares to or resale of the Shares by the Holder
or (B) the shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and
otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) trading
days after the latest of (1) the delivery to the Company of the Notice of Exercise and (2) surrender of this Warrant (if required).

 

    	 	1	 

     

    

 

(c)          Taxes.
The issuance of the Shares upon the exercise of this Warrant, and the delivery of certificates or other instruments representing
such Shares, shall be made without charge to the Holder for any tax or other charge of whatever nature in respect of such issuance
and the Company shall bear any such taxes in respect of such issuance.

 

3.             Adjustment
of Exercise Price and Number of Shares. 

 

(a)          Adjustment
for Reclassification, Consolidation or Merger. If while this Warrant, or any portion hereof, remains outstanding and unexpired
there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
entity in which the Company shall not be the surviving entity, in which the Company shall be the surviving entity but the shares
of the Company’s capital stock outstanding immediately prior to the merger are converted by virtue of the merger into other
property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company’s properties and
assets as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series of related
transactions, then, as a part of such reorganization, recapitalization, merger, consolidation, sale or transfer, unless otherwise
directed by the Holder, all necessary or appropriate lawful provisions shall be made so that the Holder shall thereafter be entitled
to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price then in effect,
the greatest number of shares of capital stock or other securities or property that a holder of the Shares deliverable upon exercise
of this Warrant would have been entitled to receive in such reorganization, recapitalization, merger, consolidation, sale or transfer
if this Warrant had been exercised immediately prior to such reorganization, recapitalization, merger, consolidation, sale or transfer,
all subject to further adjustment as provided in this Section 3. If the per share consideration payable to the Holder for
Shares in connection with any such transaction is in a form other than cash or marketable securities, then the value of such consideration
shall be determined in good faith by the Company’s Board of Directors. The foregoing provisions of this paragraph shall similarly
apply to successive reorganizations, recapitalizations, mergers, consolidations, sales and transfers and to the capital stock or
securities of any other corporation that are at the time receivable upon the exercise of this Warrant. In all events, appropriate
adjustment shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder
after the transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably
may be, in relation to any shares or other property deliverable or issuable after such reorganization, recapitalization, merger,
consolidation, sale or transfer upon exercise of this Warrant.

 

    	 	2	 

     

    

 

(b)          Adjustments
for Split, Subdivision or Combination of Shares. If the Company shall at any time subdivide (by any stock split, stock dividend,
recapitalization, reorganization, reclassification or otherwise) the Shares subject to acquisition hereunder, then, after the date
of record for effecting such subdivision, the Exercise Price in effect immediately prior to such subdivision will be proportionately
reduced and the number of Shares subject to acquisition upon exercise of the Warrant will be proportionately increased. If the
Company at any time combines (by reverse stock split, recapitalization, reorganization, reclassification or otherwise) the Shares
subject to acquisition hereunder, then, after the record date for effecting such combination, the Exercise Price in effect immediately
prior to such combination will be proportionately increased and the number of Shares subject to acquisition upon exercise of the
Warrant will be proportionately decreased.

 

(c)          Adjustments
for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof, remains outstanding and
unexpired, the holders of any class of securities as to which purchase rights under this Warrant exist at the time shall have received
or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without
payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of dividend,
then and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of such class of
security receivable upon exercise of this Warrant, and without payment of any additional consideration therefor, the amount of
such other or additional stock or other securities or property (other than cash) of the Company that such holder would hold on
the date of such exercise had it been the holder of record of the class of security receivable upon exercise of this Warrant on
the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained
such shares and/or all other additional stock available to it as aforesaid during said period, giving effect to all adjustments
called for during such period by the provisions of this Section 3.

  

(d)          Notice
of Adjustments. Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable
upon the exercise of this Warrant, then, and in each such case, the Company, within 30 days thereafter, shall give written notice
thereof to the Holder at the address of such Holder as shown on the books of the Company, which notice shall state the Exercise
Price as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant,
setting forth in reasonable detail the method of calculation of each.

 

4.             Change
in Control.

 

(a)          Upon
the written request of the Company, the Holder agrees that, in the event of a Change in Control that is not an asset sale and in
which the sole consideration is cash, either (i) the Holder shall exercise its conversion or purchase right under this Warrant
and such exercise will be deemed effective immediately prior to the consummation of such Change in Control or (ii) if the Holder
elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Change in Control. The Company shall
provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as such
Holder may request in connection with such contemplated Change in Control giving rise to such notice), which is to be delivered
to the Holder not less than 10 days prior to the closing of the proposed Change in Control.

 

(b)          Upon
the written request of the Company, the Holder agrees that, in the event of a Change in Control that is an “arms-length”
sale of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate
(as defined below) of the Company (a “True Asset Sale”), either (i) the Holder shall exercise its conversion
or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Change
in Control or (ii) if the Holder elects not to exercise the Warrant, this Warrant will continue until the expiration of the Warrant
Expiration Term if the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall
provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as such
Holder may request in connection with such contemplated Change in Control giving rise to such notice), which is to be delivered
to the Holder not less than 10 days prior to the closing of the proposed Change in Control. As used herein “Affiliate”
shall mean any person or entity that owns or controls directly or indirectly 10% or more of the stock of the Company, and any person
or entity that controls or is controlled by or is under common control with such persons or entities.

 

    	 	3	 

     

    

 

(c)          Upon
the written request of the Company, the Holder agrees that, in the event of a stock for stock Change in Control of the Company
by a publicly traded acquirer if, on the record date for the Change in Control, the fair market value of the Shares (or other securities
issuable upon exercise of this Warrant) is equal to or greater than two times the Exercise Price, the Company may require the Warrant
to be deemed automatically exercised and the Holder shall participate in the Change in Control as a holder of the Shares (or other
securities issuable upon exercise of the Warrant) on the same terms as other holders of the same class of securities of the Company.

 

(d)          Upon
the closing of any Change in Control other than those particularly described in subsections (a), (b) and (c) above of this Section
4, the successor entity, if any, and if applicable, shall assume the obligations of this Warrant, and this Warrant shall be
exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Shares were outstanding on the record date for the Change in Control and subsequent closing.
The Exercise Price and/or number of Shares shall be adjusted accordingly.

 

5.          Notices.
All notices, requests, consents and other communications required or permitted under this Warrant shall be in writing and shall
be deemed delivered (a) three business days after being sent by registered or certified mail, return receipt requested, postage
prepaid or (b) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business
day delivery or (c) on the business day of delivery if send by facsimile transmission, in each case to the intended recipient as
set forth below:

 

	If to the Company to:	 	
        NeuroOne Medical Technologies Corporation

        10006 Liatris Lane

        Eden Prairie, MN 55347

        Attention: David A. Rosa

	 	 	 
	With a copy to:	 	
        Honigman Miller Schwartz and Cohn LLP

        350 East Michigan Avenue, Suite 300

        Kalamazoo, MI 49007

        Attention: Phillip D. Torrence, Esq.

        Facsimile: 269.337.7701

 

If to the Holder at its address
as furnished in the Subscription Agreement.

 

Either party may give
any notice, request, consent or other communication under this Warrant using any other means (including personal delivery, messenger
service, facsimile transmission, first class mail or electronic mail), but no such notice, request, consent or other communication
shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Either party
may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the
other party notice in the manner set forth in this Section 5.

 

    	 	4	 

     

    

 

 

6.             Legends.
Each certificate evidencing the Shares issued upon exercise of this Warrant shall be stamped or imprinted with a legend substantially
in the following form:

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE
FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE
TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

7.             Fractional
Shares. No fractional Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round
down to the nearest whole Share the number of Shares to be issued.

 

8.             Rights
of Stockholders. The Holder shall not be entitled to vote or receive dividends or be deemed the holder of the Shares
or any other securities of the Company that may at any time be issuable on the exercise hereof for any purpose, nor shall anything
contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or any right
to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold
consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par
value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or otherwise until this Warrant shall
have been exercised and the Shares purchasable upon the exercise hereof shall have been issued, as provided herein.

  

9.             Miscellaneous.

 

(a)          This
Warrant and disputes arising hereunder shall be governed by and construed and enforced in accordance with the laws of the State
of Delaware applicable to agreements made and to be performed wholly within such State, without regard to its conflict of law rules.

 

(b)          The
headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

(c)          The
covenants of the respective parties contained herein shall survive the execution and delivery of this Warrant.

 

(d)          The
terms of this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company
and of the Holder and of the Shares issued or issuable upon the exercise hereof.

 

    	 	5	 

     

    

 

 

(e)          This
Warrant and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subject hereof.

 

(f)          The
Company shall not, by amendment of the Certificate of Incorporation or Bylaws of the Company, or through any other means, directly
or indirectly, avoid or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times
in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate
in order to protect the rights of the Holder contained herein against impairment.

 

(g)          Upon
receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in
the case of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount
to the Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense,
will execute and deliver to the Holder, in lieu thereof, a new Warrant of like date and tenor.

 

(h)          Any
provision of this Warrant may be amended, modified or waived if and only if the Holder of this Warrant and the Company has consented
in writing to such amendment, modification or waiver of any such provision of this Warrant.

 

Signature
on the Following Page

 

    	 	6	 

     

    

 

In
Witness Whereof, the parties hereto have caused this Warrant to be signed as of the date set forth above.

 

	 	THE COMPANY:
	 	 
	 	NeuroOne Medical Technologies Corporation 
	 	 	 
	 	By:	 
	 	Name:	David A. Rosa
	 	Title:	CEO

 

 

 

 

Signature
Page to Capital Stock Purchase Warrant

 

 

    	 	7	 

     

    

 

 

Exhibit
A

 

 

 

NOTICE OF EXERCISE

 

TO BE EXECUTED BY THE REGISTERED HOLDER

TO EXERCISE THIS WARRANT

 

	 	TO:	NeuroOne Medical Technologies Corporation 

 

(1)         The
undersigned hereby elects to purchase _____ shares of capital stock (the “Shares”) of NeuroOne
Medical Technologies Corporation, a Delaware corporation, or its successors or assigns (the “Company”),
pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.

 

(2)         Please
issue a certificate or certificates representing the Shares in the name of the undersigned or in such other name as is specified
below:

 

________________________________
(Holder’s Name)

 

_________________________________

_________________________________

(Address)

 

(3)         The
undersigned represents that: (a) the Shares are being acquired for the account of the undersigned for investment and not with a
view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing
or reselling such Shares; (b) the undersigned is aware of the Company’s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the
Company; (c) the undersigned is experienced in making investments of this type and has such knowledge and background in financial
and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s
own interests; (d) the undersigned understands that the Shares issuable upon exercise of this Warrant have not been registered
under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption
from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature
of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they
must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available;
(e) the undersigned is aware that the Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain
conditions are met and until the undersigned has held the Shares for the period prescribed by Rule 144, that among the conditions
for use of Rule 144 is the availability of current information to the public about the Company and that the Company has not made
such information available and has no present plans to do so; and (f) the undersigned agrees not to make any disposition of all
or any part of the Shares unless and until there is then in effect a registration statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided
the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required.

 

 

	 	By:	 
	 	Print Name: 	 

 

 

    	 	8Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

This Subscription
Agreement (this “Agreement”) is made as of _______, ____, by and among NeuroOne
Medical Technologies Corporation, a Delaware corporation (the “Company”), and the subscribers
identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”).

 

Recitals

Whereas,
the Company seeks to sell a maximum of $300,000 (or such higher amount as the Company’s Board of Directors shall determine,
the “Total Amount”) in Promissory Notes in the form annexed hereto as Exhibit
B (each, a “Note” and collectively, the “Notes”) and, subject to
Section 1.1 below, Warrants to purchase shares of the Company’s common stock as provided in the Note and in the form
of warrant agreement annexed hereto as Exhibit C (each, a “Warrant”
and collectively, the “Warrants”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”), and Rule 506(b) of Regulation D (“Regulation D”) as
promulgated under the Securities Act (the “Offering”); and

Whereas,
each Subscriber wishes to purchase a Note with the principal amount as set forth on such subscriber’s respective Signature
Page to this Agreement.

 

Now,
Therefore, in consideration of
the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Subscribers hereby agree as follows:

 

1.                 
PURCHASE OF PROMISSORY NOTES.

 

1.1             
Subscription. Each Subscriber hereby subscribes (the “Subscription”)
to purchase a Note in the amount set forth on such Subscriber’s respective signature page hereto (the “Subscription
Amount”) and a Warrant. This Subscription shall become effective when (a) it has been duly executed by the Subscriber,
(b) this Agreement has been accepted and agreed to by the Company and (c) the Company has effectuated a Closing as set forth in
Section 1.4 hereof. The minimum Subscription Amount per Subscriber shall be $50,000. Each Subscriber shall be entitled to
receive a Warrant as provided in such Subscriber’s Note.

 

1.2             
Payment for Subscription. Each Subscriber agrees that the Subscription
Amount to the Company for the amount of the Subscriber’s Subscription is to be made upon submission of this Agreement in
the form included in these Subscription Documents (as hereinafter defined) by check or by wire transfer to an account designated
by the Company.

 

1.3             
Terms and Conditions. The Company shall have the right to accept or reject
a Subscription, in whole or in part, for any reason whatsoever, including, but not limited to, the belief of the Company that a
Subscriber cannot bear the economic risk of an investment in the Company, is not capable of evaluating the merits and risks of
an investment in the Company or is not an “Accredited Investor,” as such term is defined in Rule 501 of Regulation
D promulgated under the Securities Act, or for no reason at all.

 

    	 	1	 

     

    

 

1.4             
Closing. A closing may occur once a Subscription is received by the Company
and additional closings under the Offering may take place from time to time as subscriptions are received by the Company.

 

(a)              
The closing of on the Subscriptions for the Notes and Warrants shall occur in one or more closings (collectively, the
“Closings” and each, without distinction, a “Closing”). Each Closing shall
be held remotely by the electronic exchange of documents and funds, at 10:00 a.m. Eastern Time, or at such other time and by such
means upon which the Company and the Subscribers purchasing the Notes at such Closing shall agree.

 

(b)             
The first such Closing (the “Initial Closing”) for an aggregate amount of at least $100,000
in Principal Amount of Notes (the “Minimum Amount”) shall take place on a date determined by the Company
within 10 days of the date upon which the Company shall have received Subscriptions having an aggregate principal amount equal
to the Minimum Amount. The Notes and Warrants issued at the Initial Closing shall be documented in a Schedule of Purchasers maintained
by the Company (the “Schedule of Purchasers”).

 

(c)              
At any time after the Initial Closing, to the extent that (i) Subscribers already party to this Agreement (at the time
determined, the “Existing Subscribers”) and/or (ii) additional Subscribers (the “Additional
Subscribers”) agree by execution of a signature page hereto to purchase an aggregate amount of at least $50,000 in
additional principal amount of Notes, up to a balance of the Total Amount, the Company shall, within 10 days thereafter, hold an
additional Closing with respect to the purchase of such Notes (each, a “Subsequent Closing”); provided,
however, that the aggregate purchase price of Notes issued at the Initial Closing and all Subsequent Closings may not exceed the
Total Amount unless otherwise approved by the Company’s Board of Directors, and provided further, however, that no Closing
shall occur after the five-month anniversary of the Initial Closing (subject to a one-time extension of ninety (90) days exercisable
at the sole discretion of the Company’s Board of Directors). Other than expressly provided above in this Section 1.4(c),
there shall be no conditions precedent to a Subsequent Closing. Upon each Subsequent Closing, the Company shall amend the Schedule
of Purchasers to reflect any additional purchase by the Existing Purchasers and to add any Additional Purchasers. The terms of
the transactions consummated at each Subsequent Closing shall be identical to the terms of the transactions consummated at the
Initial Closing, excepting the date of issuance of the Notes shall be the date of such Subsequent Closing. The Notes issued in
each Subsequent Closing shall be issued to the Subscribers in the principal amount shown for each Subscriber with respect to such
Subsequent Closing on the amended Schedule of Purchasers.

 

(d)             
At each Closing, the Company shall deliver to the Subscribers executed Notes in the amounts determined for each Purchaser
pursuant to this Section 1.

 

2.                 
REPRESENTATIONS AND WARRANTIES.

 

2.1             
Representations and Warranties by the Company. The Company represents
and warrants to each Subscriber, except as and to the extent set forth in the publicly available reports, schedules, forms, statements
and other documents filed by the Company with, or furnished by the Company to, the Securities and Exchange Commission (“SEC”)
on or after January 1, 2015 and before the second Business Day immediately prior to the date hereof, to the extent the relevance
of the disclosure is reasonably apparent, as follows, in each case as of the date hereof and as of each Closing:

    	 	2	 

     

    

  

(a)              
Authorization. The Company has all corporate right, power and authority to enter into this Agreement and to consummate
the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary
for the: (i) authorization execution, delivery and performance of this Agreement by the Company; (ii) authorization, sale, issuance
and delivery of the Notes and Warrants contemplated hereby and the performance of the Company’s obligations hereunder; and
(iii) authorization, issuance and delivery of the securities issuable upon exercise of the Warrants, has been taken. The securities
issuable upon exercise of the Warrants will be validly issued, fully paid and nonassessable. The issuance and sale of the securities
contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person which have not
been waived in connection with this Offering. The Company is not in default of any other obligations, including any promissory
notes or debentures.

 

(b)             
Enforceability. Assuming this Agreement has been duly and validly authorized, executed and delivered by the parties
hereto and thereto other than the Company, this Agreement is duly authorized, executed and delivered by the Company constitutes
the legal, valid and binding obligations of the Company enforceable against the Company in accordance with its terms, except as
such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the
enforcement of creditors rights generally.

 

(c)              
No Violations. The execution, delivery and performance of this Agreement and the Note by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Warrants
and the securities issuable upon the exercise of the Warrants) will not (i) result in a violation of the Certificate of Incorporation
of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree applicable to the Company by which any property or asset of the Company is bound
or affected.

 

(d)             
Litigation.

 

(i)                
The Company knows of no pending or threatened legal or governmental proceedings against the Company which could materially
adversely affect the business, property, financial condition or operations of the Company or which materially and adversely questions
the validity of this Agreement or any agreements related to the transactions contemplated hereby or the right of the Company to
enter into any of such agreements, or to consummate the transactions contemplated hereby or thereby. The Company is not a party
or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality
which could materially adversely affect the business, property, financial condition or operations of the Company. There is no action,
suit, proceeding or investigation by the Company currently pending in any court or before any arbitrator or that the Company intends
to initiate.

 

    	 	3	 

     

    

 

(ii)             
There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investigation,
proceeding or demand letter pending, or to the knowledge of the Company threatened, against the Company, which if adversely determined
would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations hereunder.
There is no civil, criminal or administrative action, suit, demand, claim, hearing, notice of violation or investigation, proceeding
or demand letter pending, or to the knowledge of the Company threatened, against or affecting the Company or any of its subsidiaries
that, if adversely determined, would reasonably be expected to have a material adverse effect on Company and its subsidiaries (taken
as a whole). There are no outstanding orders, writs, judgments, decrees, injunctions or settlements that would reasonably be expected
to have a material adverse effect on the Company and its subsidiaries (taken as a whole).

 

 

(e)              
Intellectual Property. The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks,
trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business
as now conducted without any known infringement of the rights of others. The Company has not received any written communications
alleging that the Company has violated or, by conducting its business as presently proposed to be conducted, would violate any
of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person
or entity.

 

(f)               
Title to Assets. The Company has good and marketable title to its properties and assets, and good title to its leasehold
estates, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than (i) those resulting from taxes
which have not yet become delinquent; (ii) liens and encumbrances which do not materially detract from the value of the property
subject thereto or materially impair the operations of the Company; and (iii) those that have otherwise arisen in the ordinary
course of business. The Company is in compliance with all material terms of each lease to which it is a party or is otherwise bound.

 

(g)              
Investment Company. The Company is not an “investment company” within the meaning of such term under the
Investment Company Act of 1940, as amended, and the rules and regulations of the Securities and Exchange Commission (“SEC”)
thereunder.

 

(h)             
No Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions
contemplated hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under
the Securities Act, with respect to any of the Notes being offered hereby.

 

(i)                
Blue Sky. The Company agrees to file a Form D with respect to the sale of the Notes under Regulation D of the rules
and regulations promulgated under the Securities Act. The Company shall take such action as the Company shall reasonably determine
is necessary to qualify the Notes for sale to the Subscriber pursuant to this Agreement under applicable securities or “blue
sky” laws of the states of the United States (or to obtain an exemption from such qualification).

 

    	 	4	 

     

    

 

(j)               
No Integration. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would
require registration under the Securities Act of the issuance of the Notes, the Warrants or securities issuable upon exercise of
the Warrants to the Subscriber. The issuance of the Notes, the Warrants and securities issuable upon exercise of the Warrants to
the Subscriber will not be integrated with any other issuance of the Company’s securities (past, current or future) such
that the offering of the Notes or the Warrants would require registration under the Securities Act or would require stockholder
approval.

 

(k)             
Non-Contravention. The execution, delivery and performance of this Agreement by the Company will not (i) violate any
law, treaty, rule or regulation applicable to or binding upon the Company or any of its properties or assets, or (ii) result in
a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound
that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under
this Agreement.

 

2.2             
Survival of Representations and Warranties. The representations and warranties
of the Company shall survive the Initial Closing for a period of 12 months and shall be fully enforceable at law or in equity against
the Company and the Company’s successors and assigns.

 

2.3             
Disclaimer. It is specifically understood and agreed by each Subscriber
that the Company has not made, nor by this Agreement shall be construed to make, directly or indirectly, explicitly or by implication,
any representation, warranty, projection, assumption, promise, covenant, opinion, recommendation or other statement of any kind
or nature with respect to the anticipated profits or losses of the Company, except as otherwise provided with this Agreement.

 

2.4             
Representations and Warranties by the Subscribers. Each Subscriber represents
and warrants to the Company, as of the date hereof and as of the Closing, as follows:

 

(a)              
The Subscriber is acquiring the Notes and the Warrants for the Subscriber’s own account, as principal, for investment
purposes only and not with any intention to resell, distributes or otherwise dispose of the Notes or Warrants, as the case may
be, in whole or in part.

 

(b)             
The Subscriber has had an unrestricted opportunity to: (i) obtain information concerning the Offering, including the
Notes, the Warrants, the Company and its proposed and existing business and assets; and (ii) ask questions of, and receive answers
from the Company concerning the terms and conditions of the Offering and to obtain such additional information as may have been
necessary to verify the accuracy of the information contained in the this Agreement or otherwise provided.

 

    	 	5	 

     

    

(c)              
The Subscriber is an Accredited Investor, within the meaning of SEC Rule 501 of Regulation D, and has such knowledge
and experience in financial and business matters that he is capable of evaluating the merits and risks of investing in the Company,
and all information that the Subscriber has provided concerning the Subscriber, the Subscriber’s financial position and knowledge
of financial and business matters is true, correct and complete. The Subscriber acknowledges and understands that the Company will
rely on the information provided by the Subscriber in this Agreement and in the Subscriber Questionnaire annexed hereto as Exhibit
A for purposes of complying with federal and applicable state securities laws.

 

(d)             
Except as otherwise disclosed in writing by the Subscriber to the Company, the Subscriber has not dealt with a broker
in connection with the purchase of the Notes and agrees to indemnify and hold the Company and its officers and directors harmless
from any claims for brokerage or fees in connection with the transactions contemplated herein.

 

(e)              
The Subscriber is not relying on the Company or any of its management, officers or employees with respect to any legal,
investment or tax considerations involved in the purchase, ownership and disposition of Notes or Warrants. The Subscriber has relied
solely on the advice of, or has consulted with, in regard to the legal, investment and tax considerations involved in the purchase,
ownership and disposition of Notes and Warrants, the Subscriber’s own legal counsel, business and/or investment adviser,
accountant and tax adviser.

  

(f)               
The Subscriber understands that the Notes and the Warrants, or any securities received upon exercise of the Warrants,
cannot be sold, assigned, transferred, exchanged, hypothecated or pledged, or otherwise disposed of or encumbered except in accordance
with the Securities Act or the Securities and Exchange Act of 1934, as amended (the “Exchange Act”),
and that a market may never exist for the resale of any such securities. In addition, the Subscriber understands that the Notes,
Warrants or any securities received upon exercise of the Warrants, have not been registered under the Securities Act, or under
any applicable state securities or blue sky laws or the laws of any other jurisdiction, and cannot be resold unless they are so
registered or unless an exemption from registration is available. The Subscriber understands that there is no current plan to register
the Notes, Warrants or any securities received upon exercise of the Warrants.

 

(g)              
The Subscriber is willing and able to bear the economic and other risks of an investment in the Company for an indefinite
period of time. The Subscriber has read and understands the provisions of this Agreement.

 

(h)             
The Subscriber maintains the Subscriber’s domicile, and is not merely a transient or temporary resident, at the
residence address shown on the signature page of this Agreement.

 

(i)                
The Subscriber understands that the Company has made available to the Subscriber and the Subscriber’s accountants,
attorneys and other advisors full and complete information concerning the financial structure of the Company, and any and all data
requested by the Subscriber as a basis for estimating the potential profits and losses of the Company and the Subscriber acknowledges
that the Subscriber has either reviewed such information or has waived review of such information.

 

    	 	6	 

     

    

 

(j)               
The Subscriber is not participating in the Offering as a result of or subsequent to: (i) any advertisement, article,
notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio; (ii)
any seminar or meeting whose attendees have been invited by any general solicitation or general advertising; or (iii) any registration
statement the Company may have filed with the SEC.

 

(k)             
If the Subscriber is an entity, the Subscriber is duly organized, validly existing and in good standing under the laws
of its jurisdiction of incorporation or organization, as the case may be. The Subscriber has all requisite power and authority
to own its properties, to carry on its business as presently conducted, to enter into and perform the Subscription and the agreements,
documents and instruments executed, delivered and/or contemplated hereby (collectively, the “Subscription Documents”)
to which it is a party and to carry out the transactions contemplated hereby and thereby. The Subscription Documents are valid
and binding obligations of the Subscriber, enforceable against it in accordance with their terms, except as enforceability may
be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, which
affect enforcement of creditors’ rights generally. If applicable, the execution, delivery and performance of the Subscription
Documents to which it is a party have been duly authorized by all necessary action of the Subscriber. The execution, delivery and
performance of the Subscription Documents and the performance of any transactions contemplated by the Subscription Documents will
not: (i) violate, conflict with or result in a default (whether after the giving of notice, lapse of time or both) under any contract
or obligation to which the Subscriber is a party or by which it or its assets are bound, or any provision of its organizational
documents (if an entity), or cause the creation of any lien or encumbrance upon any of the assets of the Subscriber; (ii) violate,
conflict with or result in a default (whether after the giving of notice, lapse of time or both) under, any provision of any law,
regulation or rule, or any order of, or any restriction imposed by any court or other governmental agency applicable to the Subscriber;
(iii) require from the Subscriber any notice to, declaration or filing with, or consent or approval of any governmental authority
or other third party other than pursuant to federal or state securities or blue sky laws; or (iv) accelerate any obligation under,
or give rise to a right of termination of, any agreement, permit, license or authorization to which the Subscriber is a party or
by which it is bound.

 

(l)                
The Subscriber acknowledges and agrees that the Company intends to raise additional funds to operate its business.

 

(m)           
The Subscriber acknowledges and agrees that the Company will have broad discretion with respect to the use of the proceeds
from this Offering, and investors will be relying on the judgment of management regarding the application of these proceeds.

 

(n)             
At the time the Subscriber was offered the Notes and the Warrants, it was, and at the date hereof it is, and on each
date on which the Subscriber exercises the Warrants the Subscriber will be, an “accredited investor” as defined in
Rule 501(a) under the Securities Act. The Subscriber hereby represents that neither the Subscriber nor any of its Rule 506(d) Related
Parties is a “bad actor” within the meaning of Rule 506(d) promulgated under the Securities Act. For purposes of this
Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by the “Bad Actor
disqualification” provision of Rule 506(d) of the Securities Act.

 

    	 	7	 

     

    

 

(o)              
The Subscriber understands the various risks of an investment in the Company, and has carefully reviewed the various
risk factors described in the Company’s filings with the SEC.

 

3.                 
COVENANTS OF THE SUBSCRIBERS.

 

3.1             
Right of First Offer. In the event that a Subscriber shall elect to sell
all or any portion of a Note or Warrant held by such Subscriber to any person or entity other than an Affiliate (as hereinafter
defined), such Subscriber shall first give written notice thereof to the Company, which notice shall set forth the original principal
amount of such Note and the Warrant to be sold and the sales price. For a period of 15 days after receipt of such notice, the Company
shall have the right to purchase all or any portion of such Note and Warrant at the so specified sales price, exercisable by giving
written notice thereof to such Subscriber within such 15-day period. In the event the Company fails to timely exercise such right,
such Subscriber may, subject to Section 3.2 hereof, offer and sell such Note and Warrant at the same or a higher price for
a period of 180 days after expiration of such 15-day time period. After expiration of such 180-day period, such Subscriber shall
not re-offer any of such Note or Warrant without first allowing the Company to exercise the right herein granted.

 

3.2             
Right of First Refusal. In the event that any Subscriber shall receive
and accept a bona fide offer (each, an “Offer”) from any person or entity (other than an Affiliate (as
hereinafter defined) or another original holder of Notes) to purchase all or any portion of the Notes or Warrants of such Subscriber,
such Subscriber shall give written notice thereof to the Company, which notice shall be accompanied by a copy of such offer or
a detailed description of the terms thereof (each, an “Offer Notice”). For a period of 15 days after
receipt of the Offer Notice, the Company may elect to purchase the Notes or Warrants subject to the Offer on the same terms as
are described in the Offer Notice by giving notice of such election to such Subscriber within such 15-day period. In the event
the Company fails to timely exercise such right, the Subscriber may offer and sell such Notes or Warrants to the party delivering
the Offer on the Offer Terms.

 

For purposes of this
Agreement, the term “Affiliate” shall mean: (a) for purposes of any Subscriber that is an individual,
(i) the ancestors, descendants, spouse or private, tax-exempt foundation of such Subscriber, or (ii) a trust, partnership, limited
liability company, custodianship or other fiduciary account for the benefit of such Subscriber and/or such private foundation,
ancestors, descendants or spouse; (b) for purposes of any Subscriber that is not an individual, (i) any person controlled by, or
under the control of, the Subscriber, or (ii) any member, stockholder, partner or other equity holder of such Subscriber that is
an “accredited investor”, as that term is defined in Rule 501 of Regulation D, as promulgated under the Securities
Act.

 

    	 	8	 

     

    

 

3.3             
Injunctive Relief. Each Subscriber acknowledges and agrees that any breach
of the covenants contained in this Section 3 shall constitute a material breach of this Agreement and that damages would
be an inadequate remedy in the event of such breach. Accordingly, such Subscriber agrees that the Company shall be entitled to
the remedy of specific performance in the event of any such breach and hereby consents to, and waives any right to contest, the
imposition of any injunction by a court of competent jurisdiction requested by the Company to enforce specific performance of such
covenants. Each Subscriber further agrees that should such Subscriber breach any of such covenants and force the Company to obtain
an injunction to specifically enforce such covenants, such Subscriber shall reimburse the Company for all costs incurred by the
Company in obtaining such injunction, including, without limitation, court costs and reasonable attorneys’ fees and disbursements,
all promptly upon receipt of an invoice therefor.

 

3.4             
Termination of Rights. The obligations of the Subscribers, and the rights
of the Company, under this Section 3 shall terminate upon the effective date of a registration statement for a firmly underwritten
initial public offering of the Company’s capital stock under the Securities Act.

 

4.                 
MISCELLANEOUS.

 

4.1             
Indemnification. 

 

(a)              
The Subscriber will, severally and not jointly with any other Subscribers, indemnify and hold harmless the Company and
its officers, directors, members, shareholders, partners, representatives, employees and agents, successors and assigns against
any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without
limitation, court costs, reasonable attorneys’ fees and costs of defense and investigation), amounts paid in settlement or
expenses, joint or several (collectively, “Company Claims”), reasonably incurred in investigating, preparing
or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court
or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified
party is or may be a party thereto, to which any of them may become subject insofar as such Company Claims (or actions or proceedings,
whether commenced or threatened, in respect thereof): (i) arise out of or are based upon any untrue statement or untrue statement
of a material fact made by the Subscriber and contained in this Agreement; or (ii) arise out of or are based upon any breach by
the Subscriber of any representation, warranty, or agreement made by the Subscriber contained herein; provided, however, and notwithstanding
anything to the contrary, in no event shall the liability of the Subscriber pursuant to this Section 4.2 exceed the amount
of the Note that the Subscriber purchases pursuant to this Agreement.

 

(b)             
The Company will indemnify and hold harmless each Subscriber and its officers, directors, members, shareholders, partners,
representatives, employees and agents, successors and assigns, and each other person, if any, who controls such Subscriber within
the meaning of the Securities Act against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines,
penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees and costs of defense and
investigation), amounts paid in settlement or expenses, joint or several (collectively, “Subscriber Claims”),
reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal
taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether
pending or threatened, whether or not an indemnified party is or may be a party thereto, to which any of them may become subject
insofar as such Subscriber Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of
or are based upon: (i) any blue sky application or other document executed by the Company specifically for that purpose or based
upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the
Notes under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application”);
(ii) any untrue statement or alleged untrue statement of a material fact made by the Company in this Agreement; (iii) any breach
by the Company of any representation, warranty, or agreement made by it contained herein or in the Note; or (iv) any violation
by the Company or its agents of any rule or regulation promulgated under the Securities Act applicable to the Company or its agents
and relating to action or inaction required of the Company in connection with the Offering; and will reimburse such Subscriber,
and each such officer, director or member and each such controlling person for any legal or other expenses reasonably incurred
by them in connection with investigating or defending any such Claim or action; provided, however, that the Company will not be
liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such
Subscriber or any such controlling person to the Company.

 

    	 	9	 

     

    

 

4.2             
Addresses and Notices. All notices, demands, consents, requests, instructions
and other communications to be given or delivered or permitted under or by reason of the provisions of this Agreement or in connection
with the transactions contemplated hereby shall be in writing and shall be deemed to be delivered and received by the intended
recipient as follows: (i) if personally delivered, on the business day of such delivery (as evidenced by the receipt of the personal
delivery service); (ii) if mailed certified or registered mail return receipt requested, two (2) business days after being mailed;
or (iii) if delivered by overnight courier (with all charges having been prepaid), on the business day of such delivery (as evidenced
by the receipt of the overnight courier service of recognized standing). If any notice, demand, consent, request, instruction or
other communication cannot be delivered because of a changed address of which no notice was given (in accordance with this Section
4.3, or the refusal to accept same, the notice, demand, consent, request, instruction or other communication shall be deemed
received on the second business day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands,
consents, requests, instructions and other communications will be sent to the following addresses or facsimile numbers as applicable:

 

	If to the Company to:	 	
        NeuroOne Medical Technologies Corporation

        10006 Liatris Lane

        Eden Prairie, MN 55347

        Attention: David A. Rosa

	 	 	 
	With copies to:	 	
        Honigman Miller Schwartz and Cohn LLP

        350 East Michigan Avenue, Suite 300

        Kalamazoo, MI 49007

        Attention: Phillip D. Torrence, Esq.

	 	 	 

 

    	 	10	 

     

    

 

If to the Subscriber, to the address set
forth on the signature page annexed hereto.

 

Any such person may by notice given in
accordance with this Section 4.3 to the other parties hereto designate another address or person for receipt by such person
of notices hereunder.

 

4.3             
Titles and Captions. All Article and Section titles or captions in this
Agreement are for convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend
or describe the scope or intent of any provisions hereof.

 

4.4             
Assignability. This Agreement is not transferable or assignable by the
undersigned.

 

4.5             
Pronouns and Plurals. Whenever the context may require, any pronoun used
herein shall include the corresponding masculine, feminine or neuter forms. The singular form of nouns, pronouns and verbs shall
include the plural and vice versa.

 

4.6             
Further Action. The parties shall execute and deliver all documents, provide
all information and take or forbear from taking all such action as may be necessary or appropriate to achieve the purposes of this
Agreement. Each party shall bear its own expenses in connection therewith.

 

4.7             
Applicable Law. This Agreement shall be construed in accordance with and
governed by the laws of the State of Delaware without regard to its conflict of law rules.

 

4.8             
Binding Effect. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective heirs, administrators, successors, legal representatives, personal representatives,
permitted transferees and permitted assigns. If the undersigned is more than one person, the obligation of the undersigned shall
be joint and several and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be
made by and be binding upon each such person and such person’s heirs, executors, administrators and successors.

 

4.9             
Integration. This Agreement, together with the remainder of the Subscription
Documents of which this Agreement forms a part, constitutes the entire agreement among the parties pertaining to the subject matter
hereof and supersedes and replaces all prior and contemporaneous agreements and understandings, whether written or oral, pertaining
thereto. No covenant, representation or condition not expressed in this Agreement shall affect or be deemed to interpret, change
or restrict the express provisions hereof.

 

4.10         
Amendment.  This Agreement, each Note and each Warrant may be amended
only with the written consent of the Company and such Subscriber. The conditions or observance of any term of this Agreement may
be waived (either generally or in a particular instance and either retroactively or prospectively) only by written instrument and
with respect to conditions or performance obligations benefiting the Company, by the Company, and with respect to conditions or
performance obligations benefiting the Subscriber, only by the Subscriber.

 

    	 	11	 

     

    

4.11         
Creditors.  None of the provisions of this Agreement shall be for the
benefit of or enforceable by creditors of any party.

 

4.12         
Waiver.  No failure by any party to insist upon the strict performance
of any covenant, agreement, term or condition of this Agreement or to exercise any right or remedy available upon a breach thereof
shall constitute a waiver of any such breach or of such or any other covenant, agreement, term or condition.

 

4.13         
Rights and Remedies. The rights and remedies of each of the parties hereunder
shall be mutually exclusive, and the implementation of one or more of the provisions of this Agreement shall not preclude the implementation
of any other provision.

 

4.14         
Counterparts. This Agreement may be executed in one or more counterparts,
each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to
constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

signatures
on the following pages

 

 

 

 

 

    	 	12	 

     

    

 

 

In
Witness Whereof, the undersigned has executed this Agreement on this ____ day of _______, ____.

 

	Signature of Subscriber:	 	 
	 	 	 	 
	By:	 	 	 
	Name:	 	 	Print Name of Subscriber
	Title:	 	 	 

 

	 	 	 
	Social Security Number(s) or EIN	 	 
	 	 	 
	 	 	 
	Mailing Address of Subscriber(s)	 	Residence of Subscriber(s)
	 	 	 
	 	 	 
	Street	 	Street
	 	 	 
	 	 	 
	City        State       Zip Code	 	City       State       Zip Code
	 	 	 
	If Joint Ownership, check one:	 	 

 

	 ̈ Joint Tenants with Right of Survivorship	 	 
	
         ̈ Tenants-in-Common

         ̈ Tenants by
        the Entirety
	 	 
	 ̈ Community Property	 	 
	 ̈ Other (specify): _________________________	 	 

 

	 	 
	 	Aggregate Subscription Amount 

 

	 	Method of Payment:	 ̈ Wire Transfer
	 	 	 ̈  Check

 

 

FOREGOING SUBSCRIPTION ACCEPTED:

 

NeuroOne
Medical Technologies Corporation 

 

	By:	 	 
	Name:	David A. Rosa	 
	Title:	CEO 	 

 

 

    	Signature Page to Subscription Agreement

    	 

    

 

 

Exhibit
A

 

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

 

SUBSCRIBER QUESTIONNAIRE

 

NeuroOne Medical Technologies Corporation

10006 Liatris Lane

Eden Prairie, MN 55347

 

Gentlemen:

 

The information contained
herein is being furnished to NeuroOne Medical Technologies Corporation (the “Company”) in order for the
Company to determine whether the undersigned’s subscription for Promissory Notes (the “Notes”)
and Warrants (the “Warrants”) therein may be accepted pursuant to Section 4(a)(2) of the Securities Act
of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder (“Regulation
D”). The undersigned understands that (i) the Company will rely upon the following information for purposes of complying
with Federal and applicable state securities laws, (ii) none of the Notes, the Warrants or any securities issuable thereunder will
be registered under the Securities Act in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities
Act and Regulation D, and (iii) this questionnaire is not an offer to sell nor the solicitation of an offer to buy any Notes,
Warrants or any other securities, to the undersigned.

 

The following representations
and information are furnished herewith:

 

1.       Qualification
as an Accredited Investor. Please check the categories applicable to you indicating the basis upon which you qualify
as an Accredited Investor for purposes of the Securities Act and Regulation D thereunder.

 

	 ̈	Individual with Net Worth In Excess of $1,000,000.  A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000. (Explanation: In calculating your net worth, you must exclude the value of your primary residence. This means you must exclude both the equity in your primary residence and any mortgage or other debt secured by your primary residence up to the fair market value of your primary residence; provided, however, that any indebtedness secured by your primary residence that (i) you have incurred in the 60 day period prior to the date of your subscription to the Company or (ii) is in excess of the fair market value of your primary residence should be considered a liability and deducted from your aggregate net worth. In calculating your net worth, you may include your equity in personal property and real estate (excluding your primary residence), cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate (excluding your primary residence) should be based on the fair market value of such property less debt secured by such property.)
	 	 
	 ̈	Individual with a $200,000 Individual Annual Income.  A natural person (not an entity) who had an individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

 

    	 	A-1	 

     

    

 

	 ̈	Individual with a $300,000 Joint Annual Income.  A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.
	 	 
	 ̈	Corporations or Partnerships.  A corporation, partnership, or similar entity that has in excess of $5,000,000 of assets and was not formed for the specific purpose of acquiring Notes and Warrants in the Company.
	 	 
	 ̈	Revocable Trust.  A trust that is revocable by its grantors and each of whose grantors is an accredited investor.  (If this category is checked, please also check the additional category or categories under which the grantor qualifies as an accredited investor.)
	 	 
	 ̈	Irrevocable Trust.  A trust (other than an ERISA plan) that (i) is not revocable by its grantors, (ii) has in excess of $5,000,000 of assets, (iii) was not formed for the specific purpose of acquiring Notes and Warrants, and (iv) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Company.
	 	 
	 ̈	IRA or Similar Benefit Plan.  An IRA, Keogh or similar benefit plan that covers a natural person who is an accredited investor. (If this category is checked, please also check the additional category or categories under which the natural person covered by the IRA or plan qualifies as an accredited investor.)
	 	 
	 ̈	Participant-Directed Employee Benefit Plan Account.  A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an accredited investor.  (If this category is checked, please also check the additional category or categories under which the participant qualifies as an accredited investor.)
	 	 
	 ̈	Other ERISA Plan.  An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5,000,000 or for which investment decisions (including the decision to purchase an Interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.
	 	 
	 ̈	Government Benefit Plan.  A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5,000,000.

 

 

    	 	A-2	 

     

    

 

	 ̈	Non-Profit Entity.  An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5,000,000 (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.
	 	 
	 ̈	Other Institutional Investor (check one).  

 

	 	 ̈	A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity);
	 	 ̈	A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity;
	 	 ̈	A broker-dealer registered under the Securities Exchange Act of 1934, as amended;
	 	 ̈	An insurance company, as defined in section 2(13) of the Securities Act;  
	 	 ̈	A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act;  
	 	 ̈	A small business investment company licensed under Section 301(c) or (d) of the Small Business Investment Act of 1958, as amended; or
	 	 ̈	A “private business development company” as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended.

  

	 ̈	Executive Officer or Director.  A natural person who is an executive officer, director or managing member of the Company.
	 	 
	 ̈	Entity Owned Entirely By Accredited Investors.  A corporation, partnership, private investment company or similar entity each of whose equity owners is an accredited investor.  (If this category is checked, please also check the additional category or categories under which each equity owner qualifies as an accredited investor.)
	 	 
	 ̈	I do not qualify for any of the above. 

 

 

    	 	A-3	 

     

    

 

2.       Representations
and Warranties by Limited Liability Companies, Corporations, Partnerships, Trusts and Estates. If the Subscriber is
a corporation, partnership, limited liability company or trust, the Subscriber and each person signing on behalf of Subscriber
certifies that the following responses are accurate and complete:

 

	 	 	Was the undersigned organized or reorganized for the specific purpose, or for the purpose among other purposes, of acquiring interests in the Company?
	 	 	Yes ̈	No ̈
	 	 	Will the Subscriber, at any time, invest more than 40% of Subscriber’s assets in the Company?
	 	 	Yes ̈	No ̈
	 	 	Under the Subscribing entity’s governing documents and in practice, are the Subscribing entity’s investment decisions based on the investment objectives of the Subscribing entity and its owners generally and not on the particular investment objectives of any one or more of its individual owners?
	 	 	Yes ̈	No ̈
	 	 	Does any individual shareholder, partner or member or group of shareholders, partners or members of the undersigned have the right to elect whether or not to participate in the investment of the Subscribing entity in the Company or to determine the level of participation of such partner or group therein?
	 	 	Yes ̈	No ̈
	 	 	Is the Subscribing entity authorized and qualified to become a note holder of the Company and does the Subscribing entity and the undersigned hereto further represent and warrant that such signatory has been duly authorized by the Subscribing entity to execute the Subscription Documents?
	 	 	Yes ̈	No ̈
	 	 	Is the undersigned a private investment company which is not registered under the Investment Company Act, as amended, in reliance on Section 3(c)(1) or Section 3(c)(7) thereof?
	 	 	Yes ̈	No ̈

 

    	 	A-4	 

     

    

 

 

3.       Taxpayer
ID Number; No Backup Withholding; Not a Foreign Person or Entity. If Subscriber is a “non-U.S. person or entity,”
allocations of Company income may be subject to withholding and taxation under the Internal Revenue Code, as amended (“Code”).
Subscriber acknowledges that it may be required to file U.S. income tax returns. If the Subscriber is a foreign corporation, foreign
partnership, foreign trust or foreign estate (as those terms are defined in the Code and the regulations thereunder), please contact
the Company. The Subscriber understands that the information contained in this item may be disclosed to the Internal Revenue Service
by the Company and that any false statement contained in this item could be punished by fine, imprisonment or both.

 

	 	 	Subscriber certifies that the taxpayer identification number being supplied herewith by Subscriber is Subscriber’s correct taxpayer identification number and that Subscriber is not subject to backup withholding under Section 3406 of the Code and the regulations thereunder?
	 	 	Yes ̈	No ̈
	 	 	Subscriber certifies that Subscriber is not a “Non-U.S. person” or, if an entity, that Subscribing entity is not a foreign corporation, foreign partnership, foreign trust or foreign estate, as those terms are defined the Code and the regulations thereunder.
	 	 	Yes ̈	No ̈
	 	 	If Subscriber’s non-foreign status changes or if any other information in this item changes, Subscriber agrees to notify the Company within 30 days thereafter.
	 	 	Yes ̈	No ̈

To the best of my information
and belief, the above information supplied by me is true and correct in all respects.

 

	 	 	 
	 	 	 
	 	Date:	 

 

 

 

    	 	A-5	 

     

    

 

Exhibit
B

 

PROMISSORY NOTE

 

[See attached]

 

 

    	 	B-1	 

     

    

 

Exhibit
C 

 

WARRANT

 

[See attached]

 

 

 

 

    	 	C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]